Title |
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
|
---|---|
Published in |
BMC Cancer, September 2014
|
DOI | 10.1186/1471-2407-14-686 |
Pubmed ID | |
Authors |
Jiangbo Liu, Jiguang Ma, Zheng Wu, Wei Li, Dong Zhang, Liang Han, Fengfei Wang, Katie M Reindl, Erxi Wu, Qingyong Ma |
Abstract |
Pancreatic cancer is a leading cause of cancer-related deaths in the world with a 5-year survival rate of less than 6%. Currently, there is no successful therapeutic strategy for advanced pancreatic cancer, and new effective strategies are urgently needed. Recently, an arginine deprivation agent, arginine deiminase, was found to inhibit the growth of some tumor cells (i.e., hepatocellular carcinoma, melanoma, and lung cancer) deficient in argininosuccinate synthetase (ASS), an enzyme used to synthesize arginine. The purpose of this study was to evaluate the therapeutic efficacy of arginine deiminase in combination with gemcitabine, the first line chemotherapeutic drug for patients with pancreatic cancer, and to identify the mechanisms associated with its anticancer effects. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 42 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 19% |
Student > Master | 6 | 14% |
Researcher | 6 | 14% |
Student > Bachelor | 5 | 12% |
Other | 4 | 10% |
Other | 4 | 10% |
Unknown | 9 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 24% |
Biochemistry, Genetics and Molecular Biology | 8 | 19% |
Agricultural and Biological Sciences | 5 | 12% |
Chemistry | 2 | 5% |
Immunology and Microbiology | 2 | 5% |
Other | 3 | 7% |
Unknown | 12 | 29% |